Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
subsidiary Processed

Cell Stem Cell & Regenerative Medical Technology Group

6 shared events · Importance 3 · Last updated Sep 21, 2026

Importance
3
Shared Events
6
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard

Cell Stem Cell is a wholly owned operating subsidiary of Regenerative Medical Technology Group, serving as the primary vehicle for its regenerative medicine business, including physician education and product commercialization.

89
Business
Cell Stem Cell: Wholly owned subsidiary through which RMTG operates; benefits from expansion.
Regenerative Medical Technology Group: Parent company announcing expansion; faces going-concern and liquidity issues.
Sep 08, 2026 · 6 articles
82
Business
Cell Stem Cell: As the wholly owned subsidiary through which RMTG operates and the parent of ISSCA, it is the operating vehicle for the new fellowship and the broader physician-education network spanning more than 30 countries.
Regenerative Medical Technology Group: The company is the issuer of the announcement and the parent of Cell Stem Cell and ISSCA. The fellowship launch is intended to deepen physician relationships and create an educational pathway into ISSCA AI, but near-term financial impact is limited given the early commercialization stage.
Sep 17, 2026 · 6 articles
82
Business
Cell Stem Cell: As the wholly owned subsidiary operating the ISSCA physician-education platform, it is the vehicle through which the summit is conducted and its ecosystem is showcased.
Regenerative Medical Technology Group: The OTC-listed parent announced the summit through its subsidiary and frames it as a driver of physician education and commercial engagement. The event offers visibility but no disclosed financial figures, so any share-price effect is likely limited and sentiment-driven.
Sep 21, 2026 · 6 articles
77
Business
Cell Stem Cell: Wholly owned subsidiary of RMTG, through which the expansion is conducted.
Regenerative Medical Technology Group: Parent company executing strategic expansion into Argentina, expected to strengthen its Latin American presence.
Jul 23, 2026 · 6 articles
77
Business
Cell Stem Cell: As RMTG's wholly owned subsidiary, Cell Stem Cell is the operational driver behind the growth discussed, benefiting from increased visibility.
Regenerative Medical Technology Group: RMTG is the central entity, hosting its first investor call to highlight strong first-half 2026 performance and engage shareholders. The event may enhance its credibility and investor relations.
Aug 05, 2026 · 9 articles
45
Business
Cell Stem Cell: Cell Stem Cell is the wholly owned subsidiary through which RMTG operates. The website launch indirectly supports its parent's investor relations but has no direct operational impact.
Regenerative Medical Technology Group: RMTG is the central entity, having acquired the domain and launched the investor website as part of its investor-engagement strategy. This action may modestly improve shareholder communication and transparency.
Aug 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Cell Stem Cell and Regenerative Medical Technology Group interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.